Document is current
Any future updates will be listed below
-
Authors
Kangas, Brian D. http://orcid.org/0000-0002-4597-9801
Short, Annabel K.
Luc, Oanh T.
Stern, Hal S.
Baram, Tallie Z. http://orcid.org/0000-0003-0771-8616
Pizzagalli, Diego A. http://orcid.org/0000-0002-7772-1143
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (R01DA047575)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R01 MH101521, R37 MH068376, P50 MH119467)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
- License Information
-
More Information
Article History
Received: 2 September 2021
Revised: 29 October 2021
Accepted: 29 November 2021
First Online: 17 December 2021
Competing interests
: Over the past 3 years, DAP has received funding from NIMH, Brain and Behavior Research Foundation, the Dana Foundation, and Millennium Pharmaceuticals; consulting fees from Albright Stonebridge Group, BlackThorn Therapeutics, Boehringer Ingelheim, Compass Pathway, Concert Pharmaceuticals, Engrail Therapeutics, Neurocrine Biosciences, Otsuka Pharmaceuticals, and Takeda Pharmaceuticals; one honorarium from Alkermes; stock options from BlackThorn Therapeutics. DAP has a financial interest in BlackThorn Therapeutics, which has licensed the copyright to the Probabilistic Reward Task through Harvard University. DAP’s interests were reviewed and are managed by McLean Hospital and Partners HealthCare in accordance with their conflict of interest policies. All other authors report no biomedical financial interests or potential conflicts of interest.
Free to read: This content has been made available to all.
